Subject(s)
Coronavirus , IgA Vasculitis , Kidney Diseases , Purpura , Humans , IgA Vasculitis/complications , IgA Vasculitis/diagnosis , Purpura/etiology , Immunoglobulin ASubject(s)
COVID-19 , Purpura , Humans , Masks/adverse effects , SARS-CoV-2 , Personal Protective Equipment , Purpura/etiologySubject(s)
COVID-19 , Chilblains , Dermatitis , Purpura , COVID-19/complications , Chilblains/diagnosis , Chilblains/pathology , Humans , Purpura/diagnosis , Purpura/etiology , SARS-CoV-2Subject(s)
COVID-19 , Purpura , Buttocks , Critical Illness , Humans , Purpura/diagnosis , Purpura/etiology , SARS-CoV-2ABSTRACT
BACKGROUND: Although vaccination against coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been proven generally safe, rare but potentially serious adverse reactions do occur. Leukocytoclastic vasculitis (LCV) is a small-vessel vasculitis that has been associated with other immunizations, but, to our knowledge, has not been previously reported in association with vaccines directed against SARS-CoV-2. CASE REPORT: We report the case of a 22-year-old man with no known past medical history who presented to the Emergency Department with 2 days of migratory arthritis in his ankles and palpable purpura on his bilateral lower extremities, occurring 10 days after receiving the Johnson & Johnson SARS-CoV-2 vaccine. The patient's clinical presentation was suggestive of leukocytoclastic vasculitis, and this diagnosis was confirmed on skin biopsy. Why Should an Emergency Physician Be Aware of This? Recognition of vasculitides is important for timely treatment and prevention of complications. In a patient presenting with palpable purpura after immunization against SARS-CoV-2, LCV should be promptly considered and worked up by the Emergency Physician, though management is most often entirely outpatient and the clinical course is typically mild and self-resolving.
Subject(s)
COVID-19 , Purpura , Adult , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Humans , IgA Vasculitis , Male , Purpura/etiology , SARS-CoV-2 , Vaccination , Vasculitis, Leukocytoclastic, Cutaneous , Young AdultSubject(s)
Anemia, Aplastic/diagnosis , COVID-19/diagnosis , SARS-CoV-2/isolation & purification , Anemia, Aplastic/etiology , Anemia, Aplastic/therapy , Bone Marrow Examination , COVID-19/complications , COVID-19 Nucleic Acid Testing , Diagnosis, Differential , Epistaxis/etiology , Humans , Male , Oropharynx/pathology , Pharyngitis/etiology , Purpura/etiology , Sickle Cell Trait/complications , Stem Cell Transplantation , Young AdultSubject(s)
COVID-19/pathology , Oral Ulcer/etiology , Purpura/etiology , SARS-CoV-2 , Anti-Inflammatory Agents/therapeutic use , COVID-19/diagnosis , COVID-19/therapy , Female , Humans , Immunoglobulins/therapeutic use , Methylprednisolone/therapeutic use , Oral Ulcer/pathology , Purpura/pathology , Young AdultABSTRACT
We observed ten children with a papular eruption with purpuric features during the SARS-CoV-2 pandemic in Northern Italy (May-December 2020). Histological examination showed signs of SARS-CoV-2-related dermatosis. Evidence of nucleocapsid viral proteins using SARS-CoV-2 (2019-nCoV) nucleocapsid antibody revealed cuticular staining of the deep portion of the eccrine glands in all cases.
Subject(s)
COVID-19 , Dermatitis , Purpura , Humans , Pandemics , Purpura/etiology , SARS-CoV-2Subject(s)
COVID-19 , Purpura , COVID-19 Vaccines , Humans , Purpura/etiology , SARS-CoV-2 , Vaccination/adverse effectsSubject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Eosinophils/immunology , Skin Diseases, Vascular/chemically induced , Vasculitis, Leukocytoclastic, Cutaneous/etiology , Adult , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/immunology , Dermoscopy/methods , Eosinophils/pathology , Female , Histamine Antagonists/therapeutic use , Humans , Purpura/diagnosis , Purpura/etiology , SARS-CoV-2/genetics , SARS-CoV-2/immunology , Skin Diseases, Vascular/pathology , Treatment Outcome , Vasculitis, Leukocytoclastic, Cutaneous/diagnosisABSTRACT
Cutaneous manifestations of COVID-19-SARS-CoV-2-are common and varied. Morbilliform, vesicular, and urticarial eruptions may be nonspecific initial features of the disease. Chilblainlike lesions on the fingers or toes typically occur as part of a resolution phase, signifying a milder course, whereas livedoid lesions and retiform purpura are associated with coaguloapthy and more severe disease. Additionally, a severe Kawasaki-like multisystem inflammatory syndrome rarely is seen in children. This diverse range of cutaneous manifestations in COVID-19 reflects a spectrum of host immunologic responses to SARS-CoV-2 and may inform disease pathophysiology.
Subject(s)
COVID-19/complications , Severity of Illness Index , Skin Diseases/diagnosis , Skin Diseases/etiology , COVID-19/epidemiology , COVID-19 Testing , Dermatology , Exanthema/diagnosis , Exanthema/etiology , Female , Humans , Male , Purpura/diagnosis , Purpura/etiology , Skin/pathology , Skin Diseases/virology , Skin Diseases, Viral/diagnosis , Skin Diseases, Viral/etiology , Urticaria/diagnosis , Urticaria/etiologySubject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Thrombocytopenia/etiology , 2019-nCoV Vaccine mRNA-1273 , Adult , Analgesics, Non-Narcotic/therapeutic use , COVID-19 Vaccines/therapeutic use , Chronic Disease , Dexamethasone/therapeutic use , Female , Glucocorticoids/therapeutic use , Headache/blood , Headache/drug therapy , Headache/etiology , Humans , Ibuprofen/therapeutic use , Immunoglobulins, Intravenous/therapeutic use , Platelet Count , Purpura/blood , Purpura/drug therapy , Purpura/etiology , Thrombocytopenia/blood , Thrombocytopenia/drug therapyABSTRACT
INTRODUCTION: COVID-19 is an infectious disease caused by the new coronavirus, SARS-CoV-2, that has spread rapidly throughout the world. This has resulted in an urgent need to obtain information regarding its pathogenesis, diagnosis and clinical manifestations. More specifically, skin manifestations, seldom reported initially, have been increasingly described. MATERIAL AND METHODS: We performed a literature search in the PubMed database, regarding cutaneous manifestations associated with COVID-19. This article describes the clinical and histological findings of the main skin lesions observed in the context of SARS-CoV-2 infection. DISCUSSION: Cutaneous manifestations associated with COVID-19 have been described in multiple retrospective and prospective studies, case series and case reports. The reported incidence reached 20.4%. Although there was substantial heterogeneity in terms of clinical patterns, the main ones include: erythematous/maculopapular, urticarial, papulovesicular, and purpuric/petechial eruptions, chilblain-like lesions and livedoid/acro-ischemic lesions. In the vast majority, the underlying pathophysiologic mechanisms are not fully understood, although histopathological findings and biomolecular studies can add relevant data. CONCLUSION: The recognition of cutaneous manifestations associated with COVID-19 is of utmost importance. They may help establishing an early diagnosis, namely in oligosymptomatic patients or when confirmatory tests are impossible to perform. Moreover, chilblain-like lesions and acro-ischemia, also seem to play an important role in terms of prognosis.
Introdução: A COVID-19, doença infeciosa causada por um novo coronavírus, SARS-CoV-2, propagou-se rapidamente pelo mundo inteiro, resultando numa necessidade emergente de obtenção de conhecimentos alusivos à sua patogénese, diagnóstico e sintomatologia. Mais especificamente, um número cada vez maior de casos relativos a manifestações cutâneas, previamente desconhecidas, tem vindo a ser descrito.Material e Métodos: Foi realizada uma pesquisa de literatura, através da base de dados PubMed, referente às manifestações dermatológicas associadas à COVID-19. O presente artigo descreve os achados clínicos e histológicos das principais lesões cutâneas observadas em contexto da infeção por SARS-CoV-2.Discussão: Manifestações cutâneas associadas à COVID-19 foram descritas em múltiplos estudos retrospetivos e prospetivos, séries de casos e casos clínicos isolados. A incidência reportada atingiu os 20,4%, verificando-se uma heterogeneidade de padrões clínicos substancial. Destes destacam-se as erupções eritematosas/maculopapulares, urticariformes, papulovesiculares, purpúricas/petequiais, lesões tipo-perniose e lesões livedóides/acro-isquémicas. O conhecimento dos mecanismos fisiopatológicos subjacentes tem vindo a ser enriquecido com achados os histológicos e de biologia molecular.Conclusão: É essencial o reconhecimento das manifestações dermatológicas associadas à COVID-19, uma vez que podem permitir o diagnóstico precoce da infeção, nomeadamente em casos oligossintomáticos ou quando não é possível a realização de testes confirmatórios. Embora menos estabelecido, lesões tipo-perniose e acro-isquémicas, parecem ter também um papel importante a nível prognóstico.
Subject(s)
COVID-19/complications , SARS-CoV-2 , Skin Diseases, Viral/etiology , Erythema/etiology , Erythema/pathology , Humans , Incidence , Ischemia/etiology , Ischemia/pathology , Nicolau Syndrome/etiology , Nicolau Syndrome/pathology , Prospective Studies , Purpura/etiology , Purpura/pathology , Retrospective Studies , Skin Diseases, Viral/pathology , Toes/blood supply , Urticaria/etiology , Urticaria/pathologyABSTRACT
The novel coronavirus (SARS-CoV-2), the cause of coronavirus 2019 disease (COVID-19) pandemic, is associated with some cutaneous manifestations. Although the cutaneous presentations of COVID-19 are infrequent, it is of great importance for all clinicians to be aware of these manifestations, as it may contribute to sooner and better diagnosis and management of the disease, even in asymptomatic or paucisymptomatic patients. The reported cutaneous manifestations of COVID-19 are various, dispersed, and sometimes confusing. In this article, all reported cases to date were collected and classified under 6 major groups: maculopapular rash, urticaria, chilblain, vesicular lesions, livedo reticularis, and petechiae. Different characteristics of each group were discussed in detail as well.